EverythingALS Awards Gift to the Sean M. Healey & AMG Center for ALS as part of new Vision 2030 AI Hub for ALS Research

Boston - The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has been awarded $1.25 million over five years from EverythingALS as an extension to the Vision 2030 AI Hub, an innovative model aimed at accelerating ALS research through the use of artificial intelligence (AI), machine learning (ML), and data science.

Vision 2030 comes from the minds behind Everything ALS, a leading force against the fight against ALS. Founded by CEO Indu Navar and joined by Bill Nuti as chairman, EverythingALS aims to eradicate degenerative diseases by combining advances in technological and data science research to halt the progression. Vision 2030 will serve as a global collaborative and technology-enabled research platform, uniting researchers from leading institutions and developing a ‘supply chain’ of data to be translated into breakthrough treatments for these diseases.

The MGH Vision 2030 ALS Research Hub Fund will be under the direction of Merit Cudkowicz, MD, MSc, Chair of the Department of Neurology, Director of the Healey & AMG Center for ALS, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. The gift from EverythingALS will help to establish this Hub, and support pivotal research bringing AI and new technologies for repair and regeneration research in ALS. Dr Cudkowicz will also chair the Steering Committee for Vision 2030.

A matching gift of $1.25 million was also made to ALS researcher Ernest Fraenkel, Grover M. Hermann Professor in Health Sciences and Technology in the Massachusetts Institute of Technology’s (MIT) Department of Biological Engineering. The gifts will create a pathway between MIT and MGH to increase collaboration, and eventually lead to the involvement of other institutions as part of Vision 2030.

“The Vision 2030 Research Hub brings to life the new age of scientific and medical research” says Dr. Cudkowicz. “The collaboration across institutions will pave the way for major breakthroughs in neurodegenerative disease research, illuminating hope and progress in the pursuit of effective treatments and ultimately, cures."